ZOLANTIDINE


Synonyms	SK&F-95282 Zolantidine
Molecule Category	Free-form
UNII	M1108XAY01
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	KUBONGDXTUOOLM-UHFFFAOYSA-N
Smiles	C(CNc1nc2ccccc2s1)COc3cccc(CN4CCCCC4)c3
InChI	InChI=1S/C22H27N3OS/c1-4-13-25(14-5-1)17-18-8-6-9-19(16-18)26-15-7-12-23-22-24-20-10-2-3-11-21(20)27-22/h2-3,6,8-11,16H,1,4-5,7,12-15,17H2,(H,23,24)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C22H27N3OS
Molecular Weight	381.53
AlogP	4.95
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	8.0
Polar Surface Area	65.63
Molecular species	BASE
Aromatic Rings	3.0
Heavy Atoms	27.0

Assay Description	Organism	Bioactivity	Reference
Antinociceptive activity in icv dosed Rattus norvegicus albino (rat) tus norvegicus Sprague-Dawley (rat) assessed as increase in thermal-stimulus induced tail flick latency after 5 to 10 min	Rattus norvegicus	262.0 nmol
Antinociceptive activity in icv dosed Rattus norvegicus albino (rat) tus norvegicus Sprague-Dawley (rat) assessed as maximal increase in paw withdrawal latency after 5 to 10 min by hot plate test	Rattus norvegicus	262.0 nmol

Cross References

Resources	Reference
ChEMBL	CHEMBL419296
FDA SRS	M1108XAY01
PubChem	91769
SureChEMBL	SCHEMBL10400337

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).